BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
BRISTOL MYERS SQUIBB CO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$58.83−0.92 (-1.54%)
Close on Oct 19, 2026
- Market cap
- $120.48B
- P/E (TTM)
- 13.0
- Dividend yield
- 4.23%
BRISTOL MYERS SQUIBB CO revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross product sales | $81.14B | $85.14B | $88.09B | $86.92B | $85.65B | $84.25B | $83.67B | $80.93B | $78.36B | $75.69B | $73.68B | $72.13B | 165.0% | -5.3% |
| Net product sales | $47.72B | $47.04B | $46.76B | $46.46B | $46.09B | $46.11B | $46.78B | $46.14B | $45.30B | $44.29B | $43.78B | $43.68B | 97.0% | +3.5% |
| Growth Portfolio | $28.04B | $27.07B | $26.41B | $25.38B | $24.33B | $23.33B | $22.56B | $21.46B | $20.59B | $19.74B | $19.37B | – | 57.0% | +15.2% |
| Legacy Portfolio | $21.17B | $21.42B | $21.79B | $22.66B | $23.37B | $24.30B | $25.74B | $25.98B | $25.92B | $25.79B | $25.64B | – | 43.0% | -9.4% |
| Eliquis | $15.82B | $15.02B | $14.44B | $14.19B | $13.44B | $13.18B | $13.33B | $13.01B | $12.72B | $12.50B | $12.21B | $12.02B | 32.2% | +17.7% |
| Opdivo | $9.86B | $9.93B | $10.05B | $9.84B | $9.66B | $9.49B | $9.30B | $9.21B | $9.13B | $8.89B | $9.01B | $8.84B | 20.0% | +2.0% |
| Orencia | $3.82B | $3.75B | $3.71B | $3.70B | $3.67B | $3.65B | $3.68B | $3.67B | $3.66B | $3.64B | $3.60B | $3.53B | 7.8% | +4.2% |
| Yervoy | $2.97B | $2.93B | $2.90B | $2.77B | $2.67B | $2.57B | $2.53B | $2.42B | $2.36B | $2.31B | $2.24B | $2.24B | 6.0% | +11.2% |
| Reblozyl | $2.57B | $2.40B | $2.33B | $2.21B | $2.04B | $1.90B | $1.77B | $1.55B | $1.35B | $1.16B | $1.01B | $887.00M | 5.2% | +26.0% |
| Other Growth products | $2.28B | $2.19B | $1.92B | $2.11B | $2.03B | $1.83B | $1.64B | $1.44B | $1.31B | $1.26B | $1.21B | – | 4.6% | +12.3% |
| Pomalyst/Imnovid | $2.08B | $2.59B | $2.73B | $2.86B | $3.09B | $3.34B | $3.55B | $3.61B | $3.59B | $3.47B | $3.44B | $3.43B | 4.2% | -32.5% |
| Revlimid | $1.95B | $2.36B | $2.95B | $3.69B | $4.53B | $5.04B | $5.77B | $5.88B | $5.90B | $6.02B | $6.10B | $6.91B | 4.0% | -56.9% |
| Breyanzi | $1.65B | $1.51B | $1.36B | $1.23B | $1.09B | $903.00M | $747.00M | $585.00M | $453.00M | $400.00M | $364.00M | $318.00M | 3.3% | +50.5% |
| Camzyos | $1.38B | $1.22B | $1.07B | $938.00M | $798.00M | $677.00M | $602.00M | $467.00M | $379.00M | $286.00M | $231.00M | $159.00M | 2.8% | +72.9% |
| Opdualag | $1.29B | $1.23B | $1.19B | $1.09B | $1.02B | $974.00M | $928.00M | $864.00M | $797.00M | $716.00M | $627.00M | $541.00M | 2.6% | +26.4% |
| Other Legacy products | $702.00M | $755.00M | $798.00M | $849.00M | $897.00M | $896.00M | $925.00M | $906.00M | $918.00M | $944.00M | $962.00M | – | 1.4% | -21.7% |
| Opdivo Qvantig | $624.00M | $393.00M | $238.00M | $106.00M | $39.00M | $9.00M | $0 | – | – | – | – | – | 1.3% | +1500.0% |
| Zeposia | $607.00M | $588.00M | $577.00M | $576.00M | $562.00M | $563.00M | $566.00M | $541.00M | $517.00M | $466.00M | $434.00M | $380.00M | 1.2% | +8.0% |
| Alliance revenues | $438.00M | $453.00M | $447.00M | $456.00M | $436.00M | $433.00M | $479.00M | $502.00M | $535.00M | $598.00M | $608.00M | $643.00M | 0.9% | +0.5% |
| Sprycel | $360.00M | $392.00M | $493.00M | $612.00M | $783.00M | $1.09B | $1.29B | $1.61B | $1.84B | $1.88B | $1.93B | $1.98B | 0.7% | -54.0% |
| Sotyktu | $321.00M | $304.00M | $291.00M | $288.00M | $274.00M | $257.00M | $246.00M | $226.00M | $226.00M | $198.00M | $170.00M | $114.00M | 0.7% | +17.2% |
| Abraxane | $263.00M | $313.00M | $368.00M | $458.00M | $637.00M | $763.00M | $875.00M | $948.00M | $955.00M | $982.00M | $1.00B | $936.00M | 0.5% | -58.7% |
| Krazati | $214.00M | $207.00M | $205.00M | $188.00M | $169.00M | $153.00M | $126.00M | $87.00M | $53.00M | $21.00M | $0 | – | 0.4% | +26.6% |
| Cobenfy | $212.00M | $184.00M | $155.00M | $115.00M | $72.00M | $37.00M | $10.00M | – | – | – | – | – | 0.4% | +194.4% |
| Inrebic | – | – | – | – | – | – | – | – | – | – | $110.00M | $104.00M | – | – |
| Onureg | – | – | – | – | – | – | – | – | – | – | $168.00M | $158.00M | – | – |
| Abecma | – | – | $427.00M | $432.00M | $419.00M | $427.00M | $406.00M | $401.00M | $370.00M | $407.00M | $472.00M | $497.00M | – | – |
| Alliance and other revenues | – | – | – | – | – | – | – | – | – | – | – | $1.26B | – | – |
| Total Recent LOE Products | – | – | – | – | – | – | – | – | – | – | $7.10B | $7.84B | – | – |
| In-line products and new product portfolio | – | – | – | – | – | – | – | – | – | – | $37.91B | $37.09B | – | – |
| In-line products | – | – | – | – | – | – | – | – | – | – | $34.32B | $33.93B | – | – |
| New product portfolio | – | – | – | – | – | – | – | – | – | – | $3.59B | $3.16B | – | – |
| Augtyro | – | – | – | – | – | – | $38.00M | $24.00M | $14.00M | $7.00M | $1.00M | – | – | – |
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| U S [Member] | $33.67B | $33.19B | $33.28B | $33.32B | $33.22B | $33.50B | $34.11B | $33.42B | $32.73B | $31.73B | $31.21B | $30.90B | 68.4% | +1.3% |
| International | $14.35B | $14.16B | $13.83B | $13.59B | $13.38B | $13.12B | $13.20B | – | – | – | – | – | 29.2% | +7.2% |
| Other | $1.17B | $1.13B | $1.09B | $1.13B | $1.11B | $1.02B | $996.00M | $830.00M | $744.00M | $743.00M | $699.00M | $715.00M | 2.4% | +5.9% |
| International | – | – | – | – | – | – | – | $12.84B | $12.69B | $12.71B | $12.75B | $13.00B | – | – |
From the segment and revenue-disaggregation notes of Bristol Myers Squibb's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.